On March 8, 2024, Andrew Aromando, the Company's Chief Operating Officer, resigned and ceased to be an officer of Ambrx Biopharma Inc.
Ambrx Biopharma Inc.
Equities
AMAM
US6418711080
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |